Share Prices & Company Research

Stockbroking

Circassia Pharmaceuticals

Current Price 17.15p Bid 17.00p Ask 17.15p Change 1.48%
Last Updated: 18/11/2019 19:39. Prices delayed by at least 15 minutes.
Call 0113 243 6941 or search for your local office

Company Overview

Circassia Pharmaceuticals plc is a world-class specialty pharmaceutical business focused on respiratory disease. The Company sells its novel, market-leading NIOX asthma management products directly to specialists in the United States, United Kingdom, China and Germany, and in a wide range of other countries through its network of partners. In the United States, Circassia has a commercial collaboration with AstraZeneca in which it has the commercial rights to chronic obstructive pulmonary disease (COPD) treatments Tudorza and Duaklir. Circassia also has the US and Chinese commercial rights to the late-stage ventilator-compatible nitric oxide product AirNOvent.

Financial Highlights Year Ended 31/12/2018

Turnover
£48.30m
Operating Profit
£-40.40m
Dividend Yield
0.00
Dividend Per Share
0.00
Dividend Cover
0.00
P/E Ratio
-0.50

Key Personnel

Steven Charles Andrew Harris
Chief Executive Officer
Julien Fabrice Cotta
Chief Financial Officer
Jonathan Charles Emms
Chief Operating Officer
Dr Francesco Granata
Non-Executive Chairman
Joanna Susan Le Couilliard
Non-Executive Director
Sharon Curran
Non-Executive Director

Stock Details

EPIC
CIR
ISIN
GB00BJVD3B28
Shares in Issue
375,188,718
Market cap
£63.41m
Sector

Analyst Views (2)

Strong Buy
 
50.00%
Buy
 
0.00%
Hold
 
50.00%
Sell
 
0.00%
Strong Sell
 
0.00%
The above information represents a selection of the views published in the last 120 days by analysts. It is subject to change without notice and doesn't reflect view held by Redmayne Bentley and is not advice.

Price Summary

Mid Price
17.15p
Bid Price
17.00p
Ask Price
17.15p
Volume
380274
Change Today
0.25p
% Change Today
1.48%
Open
17.19p
Previous Close
17.15p
Intraday High
17.35p
Intraday Low
16.65p
52 Week High
66.60p
52 Week Low
13.25p
52 week high and low figures quoted above are calculated from intraday price data.

Intra-Day Chart

Circassia Pharmaceuticals Intra-day Chart

Assets (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2018
31 Dec 2017
Tangible Assets
0.5
1.4
Intangible Assets & Goodwill
230.7
209.7
Investments & Other Non-Current Assets
22.2
101.4
Total Non-Current Assets
253.4
312.5
Inventory
4.2
5.0
Trade & Receivables
8.1
18.9
Cash & Receivables
40.7
44.5
Other Current Assets & Assets Held for Resale
1.0
21.5
Total Assets
307.4
402.4

Liabilities (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2018
31 Dec 2017
Short Term Liabilities
124.4
30.8
Long Term Liabilities
57.1
146.8
Other Liabilities / Pension etc
0.0
0.0
Total Liabilities
181.5
177.6

Net Assets (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2018
31 Dec 2017
Net Assets
125.9
224.8

Equity (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2018
31 Dec 2017
Share Capital
0.3
0.3
Minority Interests
0.0
0.0
Retained Earnings
-512.0
-394.9
Share Premium Account
622.5
602.2
Other Equity
15.1
17.2
Total Equity
125.9
224.8

Cashflow (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2018
31 Dec 2017
Cashflow from Operating Activities
-40.6
-57.6
Cashflow Before Financing
-25.0
-52.4
Increase / Decrease in Cash
-4.7
-54.0

Income (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2018
31 Dec 2017
Turnover
48.3
46.3
Cost of Sales
8.9
10.0
Gross Profit
39.4
36.3
Operating Profit
-40.4
-121.6
Pre-Tax Profit
-55.8
-113.6
Profit / Loss for the Year
-117.1
-99.1
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.